Global Human Vaccine Market 2016-2020

About Human Vaccine

According to the Centers for Disease Control and Prevention (CDC), a vaccine is a product that stimulates a persons immune system to produce immunity to a specific disease, protecting the person from that disease. Vaccines are usually administered through needle injections, but can also be administered by mouth or sprayed into the nose.

Human vaccines are of two types: preventable human vaccines and therapeutic human vaccines. Preventable human vaccines are used both for adults and children. Pediatric human vaccines are used to immunize children against various infectious diseases such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases.

Technavios analysts forecast the global human vaccines market to grow at a CAGR of 11.69% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global human vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of preventable and therapeutic human vaccines.

The market is divided into the following segments based on geography:
Americas
APAC
Europe

Technavios report, Global Human Vaccine Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
GlaxoSmithKline
Merck
Pfizer
Sanofi

Other prominent vendors
Abbott
AstraZeneca
Bavarian Nordic
Baxter
Bharat Biotech
Bharat Immunologicals and Biologicals
bioCSL
Bio Med
Crucell
Dynavax Technologies
Indian Immunologicals
Janssen Pharmaceuticals
Kaketsuken
LG Life Sciences
Mitsubishi Tanabe Pharma
Lupin
Nuron
Novartis
Protein Sciences Corporation
Panacea Biotec
Roche
Serum Institute of India
Shenzhen Kangtai Biological Products
Sinovac Biotech
S K Chemicals
Takeda Pharmaceutical
Valeant Pharmaceuticals
Zydus Cadila

Market driver
Growing awareness about vaccination and immunization programs
For a full, detailed list, view our report

Market challenge
Inadequate vaccination coverage
For a full, detailed list, view our report

Market trend
Increase in strategic alliance and M&A
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Vaccine approval process
Vaccines price list

PART 06: Pipeline portfolio

PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 08: Market segmentation by type of human vaccine
Live attenuated vaccine
Killed vaccine
Toxoid vaccine
Genetically modified/engineered vaccine
Synthetic vaccines
Dendritic cells vaccines
Conjugate vaccines
Subunit vaccines

PART 09: Market segmentation by composition
Mono vaccine
Combination vaccines

PART 10: Market segmentation by route of administration
Oral vaccines
Intramuscular vaccines
Intranasal vaccines
Intradermal vaccines

PART 11: Market segmentation by type of human vaccine

PART 12: Global therapeutic human vaccines market
Market overview
Market size and forecast

PART 13: Global preventable human vaccines market
Market overview
Market size and forecast

PART 14: Global pediatric preventable human vaccines market
Market size and forecast

PART 15: Global adult preventable human vaccines market
Market size and forecast

PART 16: Geographical segmentation
Human vaccines market in the Americas
Market size and forecast
Human vaccines market in EMEA
Market size and forecast
Human vaccines market in APAC
Market size and forecast

PART 17: Market drivers
Growing awareness about vaccination and immunization programs
Inclusion in national immunization schedule
High demand for pediatric vaccines
Increase in prevalence of infectious diseases

PART 18: Impact of drivers

PART 19: Market challenges
Inadequate vaccination coverage
Vaccine storage and handling issues
High risk associated with vaccine development
Stringent regulatory process
Misperception about vaccines
Adverse side effects of vaccines

PART 20: Impact of drivers and challenges

PART 21: Market trends
Increase in strategic alliance and M&A
Entry of novel vaccines
Increase in investment
Focus on emerging markets
Emergence of resistant strains
Public-private initiatives

PART 22: Vendor landscape
Competitive scenario

PART 23: Key vendor analysis
GSK
Sanofi
Merck
Pfizer
Other prominent vendors

PART 24: Appendix
List of abbreviations

PART 25: Explore Technavio


List Of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Requirements for BLA submission in the US
Exhibit 03: Developmental steps required to reach the vaccine licensing stage
Exhibit 04: Vaccine development process over a period of up to 15 years at a cost of up to $1 billion
Exhibit 05: Regulatory testing of licensed vaccines
Exhibit 06: Pediatric/VFC vaccine price list
Exhibit 07: Pediatric influenza vaccine price list
Exhibit 08: Adult vaccine price list
Exhibit 09: Adult influenza vaccine price list
Exhibit 10: GlaxoSmithKline: Vaccine pipeline
Exhibit 11: Novartis: Vaccine pipeline
Exhibit 12: Merck: vaccine pipeline
Exhibit 13: Pfizer: vaccine pipeline
Exhibit 14: Sanofi: vaccine pipeline
Exhibit 15: TuBerculosis Vaccine Initiative (TBVI): vaccine pipeline
Exhibit 16: Some pipeline compounds under development in 2015
Exhibit 17: Top 10 pharmaceutical companies based on global vaccine revenues in 2014 ($ millions)
Exhibit 18: Global human vaccines market 2015-2020 ($ billions)
Exhibit 19: SWOT analysis
Exhibit 20: Five forces analysis
Exhibit 21: Global human vaccines market segmentation by type of vaccine
Exhibit 22: Examples of vaccines by type
Exhibit 23: Global human vaccines market segmentation by composition
Exhibit 24: Global human vaccines market segmentation by route of administration
Exhibit 25: Route of administration for different vaccines
Exhibit 26: Global human vaccines market types
Exhibit 27: Global preventable and therapeutic human vaccines market share 2015
Exhibit 28: Global therapeutic human vaccines market 2015-2020 ($ billions)
Exhibit 29: Global preventable human vaccines market 2015-2020 ($ billions)
Exhibit 30: Global preventable human vaccines market categories
Exhibit 31: Global pediatric and adult preventable human vaccines market share 2015
Exhibit 32: Global pediatric preventable human vaccines market segmentation 2015
Exhibit 33: Global pediatric preventable human vaccines market 2015-2020 ($ billions)
Exhibit 34: Global adult preventable human vaccines market share 2015
Exhibit 35: Global adult preventable human vaccines market 2015-2020 ($ billions)
Exhibit 36: Global human vaccines market by geography 2015
Exhibit 37: Global human vaccines market by region 2015-2020 ($ billions)
Exhibit 38: Human vaccines market in the Americas 2015-2020 ($ billions)
Exhibit 39: Human vaccines market in EMEA 2015-2020 ($ billions)
Exhibit 40: Human vaccines market in APAC 2015-2020 ($ billions)
Exhibit 41: Impact of drivers
Exhibit 42: Global immunization coverage 2014
Exhibit 43: A typical cold chain process
Exhibit 44: Adverse effects associated with some preventable human vaccines
Exhibit 45: Impact of drivers and challenges
Exhibit 46: M&A in the vaccine industry
Exhibit 47: Overview of major vaccine-related acquisitions (2005-2012)
Exhibit 48: Market share analysis of top pharma vaccine companies, 2014
Exhibit 49: GSK: Business segmentation by revenue 2014
Exhibit 50: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 51: GSK: Geographical segmentation by revenue 2014
Exhibit 52: GSK: YoY revenue growth of Infanrix/Pediarix 2012-2014 ($ millions)
Exhibit 53: GSK: YoY revenue growth of Hepatitis vaccine 2012-2014 ($ millions)
Exhibit 54: GSK: YoY revenue growth of Synflorix 2012-2014 ($ millions)
Exhibit 55: GSK: YoY revenue growth of Rotarix 2012-2014 ($ millions)
Exhibit 56: GSK: YoY revenue growth of Boostrix 2012-2014 ($ millions)
Exhibit 57: GSK: Meningitis vaccine revenue 2013 and 2014 ($ millions)
Exhibit 58: GSK: Travel and paediatrics vaccine revenue 2013 and 2014 ($ millions)
Exhibit 59: Key takeaways
Exhibit 60: Sanofi: Business segmentation by revenue 2014
Exhibit 61: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 62: Sanofi: Geographical segmentation by revenue 2014
Exhibit 63: Sanofi: YoY revenue growth of Polio/pertussis/Hib vaccines ($ millions)
Exhibit 64: Sanofi: YoY revenue growth of influenza vaccines 2012-2014 ($ millions)
Exhibit 65: Sanofi: YoY revenue growth of meningitis/pneumonia vaccine 2012-2014 ($ millions)
Exhibit 66: Sanofi: YoY revenue growth of adult booster vaccine 2012-2014 ($ millions)
Exhibit 67: Sanofi: YoY revenue growth of travel and other endemic vaccines 2012-2014 ($ millions)
Exhibit 68: Key takeaways
Exhibit 69: Merck: Business segmentation by revenue 2014
Exhibit 70: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 71: Merck: Geographical segmentation by revenue 2014
Exhibit 72: Merck: YoY revenue growth of Gardasil 2012-2014 ($ millions)
Exhibit 73: Merck: YoY revenue growth of ProQuad/MMR II/Varivax 2012-2014 ($ millions)
Exhibit 74: Merck: YoY revenue growth of Zostavax 2012-2014 ($ millions)
Exhibit 75: Merck: YoY revenue growth of Pneumovax 23 2012-2014 ($ millions)
Exhibit 76: Merck: YoY revenue growth of RotaTeq 2012-2014 ($ millions)
Exhibit 77: Key takeaways
Exhibit 78: Pfizer: Business segmentation by revenue 2014 0
Exhibit 79: Pfizer: Business segmentation by revenue 2013 and 2014 ($ billions) 1
Exhibit 80: Pfizer: Geographical segmentation by revenue 2014 2
Exhibit 81: Pfizer: YoY revenue growth of Prevnar family 2012-2014 ($ millions) 3
Exhibit 82: Key takeaways